<unk>  is a adeno-associated virus vector-based gene therapy that is FDA approved for the treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy in patients who have viable retinal cells as determined by the treating physician(s).   Common adverse reactions include conjunctival hyperemia, cataract, increased intraocular pressure, retinal tear, dellen (thinning of the corneal stroma), macular hole, subretinal deposits, eye inflammation, eye irritation, eye pain, and maculopathy (wrinkling on the surface of the macula).
Voretigene neparvovec
Mecasermin rinfabate
Masoprocol
Crofelemer
Telotristat ethyl
Levonorgestrel 
Ulipristal acetate
Tegaserod